C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210)
11/2002
11/14/2002	US20020168397 Antiallergens, antiinflammatory agents; oral administering
11/14/2002	US20020168392 Antimicrobial proteins
11/14/2002	US20020168385 Adeno-associated virus vector for boosting immunogenicity of cells
11/14/2002	US20020168384 Vaccine for poultry respiratory disorders
11/14/2002	US20020168382 Inducing immunology response
11/14/2002	US20020168381 Mixture of bone protein and ethylene oxide-propylene oxide copolymer; in situ administering
11/14/2002	US20020168380 Moderating immunology response
11/14/2002	US20020168379 Veterinary medicine; swine respiratory system disorders
11/14/2002	US20020168377 Prion protein dimers useful for vaccination
11/14/2002	US20020168376 Plant extracts; sensitization of an animal; screening
11/14/2002	US20020168375 Biosynthetic binding proteins for immuno-targeting
11/14/2002	US20020168373 House dust mite allergen, Der f VII, and uses therefor
11/14/2002	US20020168367 Novel immunoadhesins for treating and preventing viral and bacterial diseases
11/14/2002	US20020168365 Method for modulating granzyme B uptake and for identifying modulators thereof
11/14/2002	US20020168363 Integrin/adhesion antagonists
11/14/2002	US20020168362 Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
11/14/2002	US20020168361 An isolated protein comprising a soluble CD97 alpha subunit, and soluble subunit is selected from the group alpha 1, alpha 2, and alpha 3, originate as proprotein with beta subunit
11/14/2002	US20020168360 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphanubeta3 antagonists in combination with other prophylactic or therapeutic agents
11/14/2002	US20020168357 Administering to a mammal an antibody capable of binding native tissue factor, and linked covalently to a cell antigen or an effector molecule to provide complement fixing ability and antibody dependent cell mediated cytotoxicity
11/14/2002	US20020168355 Cationic liposome delivery of taxanes to angiogenic blood vessels
11/14/2002	US20020168351 Fusion cells and cytokine compositions for treatment of disease
11/14/2002	US20020168349 A viral DNA construct encoding for a virus capable of replication in a human or animal tumor cell and causing death of such tumor cells
11/14/2002	US20020168346 Contain three vectors which collectively encode retroviral gag, pol, and envelop proteins, and the gag and pol genes are separated, in part, onto two or more different vectors by fusing Vpr or Vpx to pol proteins separated from gag
11/14/2002	US20020168345 Methods of monitoring HIV drug resistance using adenoviral vectors
11/14/2002	US20020168343 Combines transductional targeting via binding to angiotensin converting enzyme expressed on pulmonary endothelial cells with transcriptional targeting using vascular endothelial growth factor type 1 receptor promoter
11/14/2002	US20020168342 Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
11/14/2002	US20020168341 Enhanced system for construction of adenovirus vectors
11/14/2002	US20020168340 For inhibiting and treating HIV-1 and HIV-2 infections
11/14/2002	US20020168338 Compositions and methods for delivery of agents for neuronal regeneration and survival
11/14/2002	DE10122990A1 Verwendung von Alkanen zur kontaminationsfreien Reinigung bzw. Trennung von Biopolymeren Use of alkanes for contamination-free cleaning and separation of biopolymers
11/14/2002	DE10116829A1 Neuropeptid bindende Nukleinsäuren Neuropeptide binding nucleic acids
11/14/2002	DE10112515A1 Detecting methylation status of test DNA in a mixture, useful for diagnosis and prognosis of disease, comprises bisulfite treatment then selective amplification of test DNA
11/14/2002	CA2709843A1 Transgenic high tryptophan plants
11/14/2002	CA2458207A1 Determination of a genetic predisposition for behavioural disorders
11/14/2002	CA2452844A1 Dose response-based methods for identifying receptors having alterations in signaling
11/14/2002	CA2452245A1 Recombinant fusion proteins and the trimers thereof
11/14/2002	CA2447407A1 Nucleic acids and proteins with thioredoxin reductase activity
11/14/2002	CA2447386A1 System for discovery of agents that block yersinia pestis and pseudomonas aeruginosa dna replication
11/14/2002	CA2446998A1 Use of phosphorothiolate polynucleotides in ligating nucleic acids
11/14/2002	CA2446967A1 Novel human kinases and polynucleotides encoding the same
11/14/2002	CA2446838A1 Novel mutation
11/14/2002	CA2446825A1 Methods for determining the prognosis for cancer patients using tucan
11/14/2002	CA2446819A1 Dna molecules encoding macaca mulatta androgen receptor
11/14/2002	CA2446810A1 Epidermal growth factor receptorantisense oligonucleotides
11/14/2002	CA2446788A1 Compositions and methods for the therapy and diagnosis of prostate cancer
11/14/2002	CA2446666A1 Method for detecting progredient chronic dementia, and associated peptides and detection reagents
11/14/2002	CA2446643A1 Materials and methods for producing tomato yellow leaf curl virus resistance in plants
11/14/2002	CA2446640A1 .beta.-amyloid peptide-binding proteins and polynucleotides encoding the same
11/14/2002	CA2446626A1 Methods for the reduction of stutter in microsatellite amplification
11/14/2002	CA2446531A1 Design of artificial genes for use as controls in gene expression analysis systems
11/14/2002	CA2446458A1 Toll/interleukin-1 receptor adaptor protein (tirap)
11/14/2002	CA2446443A1 Methods for the reduction of stutter in microsatellite amplification using sorbitol
11/14/2002	CA2446437A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
11/14/2002	CA2446411A1 Products containing charged biomaterials and method for the preparation thereof
11/14/2002	CA2446394A1 Insulinotropic peptide derivatives
11/14/2002	CA2446274A1 Novel regulatory protein
11/14/2002	CA2446262A1 Method and apparatus for high-speed approximate sub-string searches
11/14/2002	CA2446258A1 Transgenic high tryptophan plants
11/14/2002	CA2446207A1 A high throughput assay for identification of gene expression modifiers
11/14/2002	CA2446204A1 Anti-virus agent
11/14/2002	CA2446087A1 Recombinant tumor specific antibody and use thereof
11/14/2002	CA2446036A1 A method for transfection of rna using electrical pulses
11/14/2002	CA2446031A1 Process for synthesizing protein using cell-free protein synthesis system
11/14/2002	CA2446022A1 Freeze-tolerant eukaryotic cells
11/14/2002	CA2445989A1 Colon cancer antigen panel
11/14/2002	CA2445982A1 Sperm-specific cation channel, and uses therefor
11/14/2002	CA2445781A1 Peptidylarginine deiminase 6
11/14/2002	CA2445049A1 Rapidly cleavable sumo fusion protein expression system for difficult to express proteins
11/14/2002	CA2444736A1 Skin treatment
11/14/2002	CA2444020A1 Novel methods of directed evolution
11/14/2002	CA2438978A1 Isolated nucleic acid molecules encoding a novel human signal transducing kinase-mapkap-2; encoded proteins, cells transformed therewith and uses thereof
11/14/2002	CA2435142A1 Kinases and phosphatases
11/14/2002	CA2430201A1 Functional protein expression for rapid cell-free phenotyping
11/14/2002	CA2429941A1 Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases
11/14/2002	CA2414073A1 Diagnostic markers of acute coronary syndromes and methods of use thereof
11/13/2002	EP1256805A2 Biological material chip
11/13/2002	EP1256632A2 High throughput polymorphism screening
11/13/2002	EP1256631A1 Instrument for monitoring nucleic acid amplification reactions
11/13/2002	EP1256630A2 Selective polymerase chain reaction of DNA of which base sequence is completely unknown
11/13/2002	EP1256629A1 Leaf specifc gene promoter of coffee
11/13/2002	EP1256628A2 Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
11/13/2002	EP1256627A2 Use of alkanes for contamination-free purification or separation of biopolymers
11/13/2002	EP1256626A1 Support for fixing nucleotide and process for producing the same
11/13/2002	EP1256625A1 Immortalized vascular adventitial cell line
11/13/2002	EP1256606A2 Pigment containing ink and production method thereof
11/13/2002	EP1256589A2 Oligomers containing modified pyrimidines
11/13/2002	EP1256354A1 Methods for treating cancer
11/13/2002	EP1256352A2 Immunomodulatory peptides
11/13/2002	EP1255998A1 Molecular impriniting compositions and methods for binding and analyzing macromolecules
11/13/2002	EP1255997A2 Composite membranes for assaying biomolecules
11/13/2002	EP1255993A2 Methods for identifying modulators for balance related disorders
11/13/2002	EP1255870A2 5-hydroxytryptamine transporter gene polymorphisms
11/13/2002	EP1255869A1 Nucleic acids, proteins, and antibodies
11/13/2002	EP1255868A1 Altered recombinases for genome modification
11/13/2002	EP1255867A2 Method for detecting a biological entity in a sample
11/13/2002	EP1255866A1 Microarray methods utilizing semiconductor nanocrystals
11/13/2002	EP1255864A1 Nucleic acids, proteins, and antibodies
11/13/2002	EP1255861A1 Methods and kits for proximity probing
11/13/2002	EP1255860A2 Methods for amplifying and detecting multiple polynucleotides on a solid phase support
11/13/2002	EP1255859A2 Tissue specific genes of diagnostic import

1 ... 2662 2663 2664 2665 2666 2667 2668 2669 2670 2671 2672 2673 2674 2675 2676 2677 2678 2679 2680 2681 2682 ... 4023